ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Anyone succeeding in increasing T with Kisspeptin while on TRT
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 239564" data-attributes="member: 3"><p>I am yet to see a single study on the use of injectable kisspeptin with TRT in humans. It is not FDA-approved, and the only data I found comes from a small study done using it alone with a single IV bolus and an 11 hour IV in men with diabetes and low testosterone. Whoever is telling patients that injecting it along with TRT can replace hCG is making up stories. But if anyone has any data to dispute with me, please let me know.</p><p></p><p></p><p> Clin Endocrinol (Oxf). 2013 Jul;79(1):100-4. doi: 10.1111/cen.12103. Epub 2013 Apr 19.</p><p></p><p><strong>Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism</strong></p><p></p><p>Jyothis T George 1, Johannes D Veldhuis, Manuel Tena-Sempere, Robert P Millar, Richard A Anderson</p><p>Affiliations expand</p><p>PMID: 23153270 DOI: 10.1111/cen.12103</p><p>Abstract</p><p>Rationale: Low serum testosterone is commonly observed in men with type 2 diabetes (T2DM), but the neuroendocrine pathophysiology remains to be elucidated.</p><p></p><p>Objectives: The hypothalamic neuropeptide kisspeptin integrates metabolic signals with the reproductive axis in animal models. We hypothesized that administration of exogenous kisspeptin-10 will restore luteinizing hormone (LH) and testosterone secretion in hypotestosteronaemic men with T2DM.</p><p></p><p>Participants: Five hypotestosteronaemic men with T2DM (age 33·6 ± 3 years, BMI 40·6 ± 6·3, total testosterone 8·5 ± 1·0 nmol/l, LH 4·7 ± 0·7 IU/l, HbA1c 7·4±2%, duration of diabetes <5 years) and seven age-matched healthy men. EXPERIMENT 1: Mean LH increased in response to<strong> intravenous administration of kisspeptin-10 (0·3 mcg/kg bolus) </strong>both in healthy men (5·5 ± 0·8 to 13·9 ± 1·7 IU/l P < 0·001) and in men with T2DM (4·7 ± 0·7 to 10·7 ± 1·2 IU/l P = 0·02) with comparable ΔLH (P = 0·18). EXPERIMENT 2: Baseline 10-min serum sampling for LH and hourly testosterone measurements were performed in four T2DM men over 12 h. <strong>An intravenous infusion of kisspeptin-10 (4 mcg/kg/h)</strong> was administered for <strong>11 h</strong>, 5 days later. There were increases in LH (3·9 ± 0·1 IU/l to 20·7 ± 1·1 IU/l P = 0·03) and testosterone (8·5 ± 1·0 to 11·4 ± 0·9 nmol/l, P = 0·002). LH pulse frequency increased from 0·6 ± 0·1 to 0·9 ± 0 pulses/h (P = 0·05) and pulsatile component of LH secretion from 32·1 ± 8·0 IU/l to 140·2 ± 23·0 IU/l (P = 0·007).</p><p></p><p>Conclusions: Kisspeptin-10 administration increased LH pulse frequency and LH secretion in hypotestosteronaemic men with T2DM in this proof-of-concept study, with associated increases in serum testosterone. These data suggest a potential novel therapeutic role for kisspeptin agonists in enhancing endogenous testosterone secretion in men with T2DM and central hypogonadism.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 239564, member: 3"] I am yet to see a single study on the use of injectable kisspeptin with TRT in humans. It is not FDA-approved, and the only data I found comes from a small study done using it alone with a single IV bolus and an 11 hour IV in men with diabetes and low testosterone. Whoever is telling patients that injecting it along with TRT can replace hCG is making up stories. But if anyone has any data to dispute with me, please let me know. Clin Endocrinol (Oxf). 2013 Jul;79(1):100-4. doi: 10.1111/cen.12103. Epub 2013 Apr 19. [B]Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism[/B] Jyothis T George 1, Johannes D Veldhuis, Manuel Tena-Sempere, Robert P Millar, Richard A Anderson Affiliations expand PMID: 23153270 DOI: 10.1111/cen.12103 Abstract Rationale: Low serum testosterone is commonly observed in men with type 2 diabetes (T2DM), but the neuroendocrine pathophysiology remains to be elucidated. Objectives: The hypothalamic neuropeptide kisspeptin integrates metabolic signals with the reproductive axis in animal models. We hypothesized that administration of exogenous kisspeptin-10 will restore luteinizing hormone (LH) and testosterone secretion in hypotestosteronaemic men with T2DM. Participants: Five hypotestosteronaemic men with T2DM (age 33·6 ± 3 years, BMI 40·6 ± 6·3, total testosterone 8·5 ± 1·0 nmol/l, LH 4·7 ± 0·7 IU/l, HbA1c 7·4±2%, duration of diabetes <5 years) and seven age-matched healthy men. EXPERIMENT 1: Mean LH increased in response to[B] intravenous administration of kisspeptin-10 (0·3 mcg/kg bolus) [/B]both in healthy men (5·5 ± 0·8 to 13·9 ± 1·7 IU/l P < 0·001) and in men with T2DM (4·7 ± 0·7 to 10·7 ± 1·2 IU/l P = 0·02) with comparable ΔLH (P = 0·18). EXPERIMENT 2: Baseline 10-min serum sampling for LH and hourly testosterone measurements were performed in four T2DM men over 12 h. [B]An intravenous infusion of kisspeptin-10 (4 mcg/kg/h)[/B] was administered for [B]11 h[/B], 5 days later. There were increases in LH (3·9 ± 0·1 IU/l to 20·7 ± 1·1 IU/l P = 0·03) and testosterone (8·5 ± 1·0 to 11·4 ± 0·9 nmol/l, P = 0·002). LH pulse frequency increased from 0·6 ± 0·1 to 0·9 ± 0 pulses/h (P = 0·05) and pulsatile component of LH secretion from 32·1 ± 8·0 IU/l to 140·2 ± 23·0 IU/l (P = 0·007). Conclusions: Kisspeptin-10 administration increased LH pulse frequency and LH secretion in hypotestosteronaemic men with T2DM in this proof-of-concept study, with associated increases in serum testosterone. These data suggest a potential novel therapeutic role for kisspeptin agonists in enhancing endogenous testosterone secretion in men with T2DM and central hypogonadism. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Anyone succeeding in increasing T with Kisspeptin while on TRT
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top